Pyridazinone derivatives, their preparation methods and applications

By designing pyridazinone derivatives that integrate PARP7 and NAMPT inhibitory effects into the same molecule, the problem of dosage ratio and interaction of existing dual-target drugs in tumor treatment has been solved, enabling simultaneous intervention in tumor immune regulation and metabolic processes, thereby enhancing the anti-tumor effect.

CN123106632APending Publication Date: 2026-11-17TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611470329.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-21
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing PARP7 inhibitors and NAMPT inhibitors have problems in cancer treatment, such as complex drug dosage ratios, inconsistent pharmacokinetic properties, increased risk of drug interactions, and poor clinical convenience. They are difficult to cover multiple key aspects of the tumor development process, such as inherent immunosuppression, abnormal immune metabolism, and enhanced metabolic dependence.

Method used

To develop a pyridazinone derivative that integrates the inhibitory effects of PARP7 and NAMPT into the same molecule, forming a dual-target small molecule compound that can act on both PARP7 and NAMPT targets simultaneously, intervening in tumor immune regulation and NAD+ metabolism-related processes.

Benefits of technology

This approach enables simultaneous intervention on both PARP7 and NAMPT targets in a single chemical entity, enhancing anti-tumor efficacy and avoiding the complexities of combination therapy. It possesses significant drug development value and anti-tumor potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_14
    Figure SMS_14
  • Figure SMS_15
    Figure SMS_15
Patent Text Reader

Abstract

This invention discloses pyridazinone derivatives, their preparation methods, and applications, belonging to the field of medicinal chemistry. This invention integrates a PARP7 inhibition-related pyridazinone structure and a NAMPT inhibition-related structural fragment into the same molecule, obtaining a single small molecule compound capable of simultaneously targeting both PARP7 and NAMPT. The compounds of this invention were verified by PARP7 enzyme activity inhibition experiments and NAMPT enzyme activity inhibition experiments, showing dual-target inhibitory activity. Some compounds exhibited IC50 values ​​against PARP7. 50 Up to 12 nM, for NAMPT IC 50 The concentration can reach 116 nM; MTT assay showed that some compounds exhibited good anti-proliferative activity against CT26 mouse colon cancer cells and NCI-H1373 human lung adenocarcinoma cells. This invention also provides methods for preparing the derivatives, pharmaceutical compositions, and their application in the preparation of antitumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of medicinal chemistry technology, specifically relating to pyridazinone derivatives, their preparation methods, and applications. Background Technology Poly(ADP-ribose) polymerases (PARPs) are a family of important enzymes involved in fundamental biological processes such as gene expression, DNA damage repair, protein post-translational modification, protein degradation, and cellular stress responses. Poly(ADP-ribose) polymerase 7 (PARP7) is an important member of the PARP family and is regulated by the aryl hydrocarbon receptor (AHR). PARP7 can transfer only one ADP-ribose to a substrate protein, classifying it as a mono-ADP-ribosyltransferase. PARP7-mediated mono-ADP-ribosylation is a reversible post-translational modification of proteins, participating in various important biological processes such as immune cell function, transcriptional regulation, protein expression, cellular stress responses, and maintenance of genome stability.

[0002] PARP7 plays a crucial role in neuronal development, stem cell maintenance, antiviral infection, and cancer. Studies have shown that PARP7 is closely related to tumorigenesis and tumor immune regulation. PARP7 is overactive in many tumors, interfering with the interferon signaling pathway and enabling cancer cells to escape immune signals. Aberrantly expressed or activated PARP7 can weaken tumor cells' ability to respond to nucleic acid sensing signals and antiviral-like immune responses by inhibiting the type I interferon signaling pathway, thereby promoting tumor immune escape, tumor cell growth, and survival. PARP7 is also considered a negative regulator of T cell activation, playing a vital role in the formation of the tumor immunosuppressive microenvironment. Inhibiting PARP7 can restore IFN-β expression in tumor cells, thereby activating T cell-mediated in vivo anti-tumor immunity. Therefore, PARP7 is considered a novel immunomodulatory target for cancer treatment. Currently, only one PARP7 selective inhibitor, RBN-2397, has entered clinical trials. Pyridazinone structures are an important structural type in PARP7 inhibitor research, serving as the core framework for designing small molecule PARP7 inhibitors and possessing value for further structural modification and drug development.

[0003] Nicotinamide phosphoribosyltransferase (NAMPT) is a nicotinamide adenine dinucleotide (NAD) +The rate-limiting enzyme in the salvage pathway can catalyze the conversion of nicotinamide to nicotinamide mononucleotide, thereby maintaining intracellular NAD+. + Horizontal. NAD + It is involved in cellular energy metabolism, redox homeostasis, DNA repair, and various NAD+ functions. + NAMPT is an essential cofactor for NAD+-dependent enzyme reactions. It is overexpressed in many cancers, including breast cancer, ovarian cancer, and gastric cancer, and is closely associated with poor prognosis and tumor progression. Tumor cells, due to their rapid proliferation, active metabolism, and enhanced stress response, typically resist NAMPT-mediated NAD+ reactions. + The salvage synthesis pathway is highly dependent. Inhibition of NAMPT reduces intracellular NAD. + At certain levels, it interferes with the energy metabolism and redox balance of tumor cells, thereby inhibiting tumor cell proliferation and inducing cell death.

[0004] In addition to being NAD + Besides being the rate-limiting enzyme in salvage pathways, NAMPT is also closely related to the regulation of the tumor immune microenvironment. Studies have shown that NAMPT-related signaling can participate in processes such as the release of inflammatory factors, recruitment of myeloid immunosuppressive cells, maintenance of the immunosuppressive microenvironment, and tumor immune escape. Extracellular NAMPT also has cytokine-like functions, participating in inflammatory responses, immune cell recruitment, and tumor microenvironment remodeling. Therefore, targeting NAMPT can not only intervene in tumor cell NAD... + Metabolic dependence may also weaken the support of the tumor immunosuppressive microenvironment for tumor progression by regulating the tumor immune metabolic state.

[0005] Existing PARP7 inhibitors primarily exert their effects by inhibiting PARP7-mediated single ADP-ribosylation, thereby relieving PARP7's negative regulation of the type I interferon signaling pathway and enhancing the innate immune response and anti-tumor immune-related signals in tumor cells. However, single PARP7 inhibitors have limited effect on NAD in tumor cells. + Interventions for metabolic reprogramming, abnormal energy metabolism, and immune metabolic adaptation processes are limited. Existing NAMPT inhibitors primarily work by blocking NAD+. + The salvage synthesis pathway exerts its antitumor effects and may influence NAMPT-related immunometabolic regulation, but it lacks a direct effect on PARP7-mediated type I interferon signaling inhibition. Furthermore, the use of NAMPT inhibitors alone may result in a limited therapeutic window, toxicity to normal proliferating tissues, metabolic adaptation in tumor cells, and the need for alternative NAD+. + Issues such as synthetic pathway compensation exist. Therefore, neither a single PARP7 inhibitor nor a single NAMPT inhibitor can simultaneously cover multiple key aspects of tumor development and progression, including inherent immunosuppression, abnormal immune metabolism, and metabolically dependent enhancement.

[0006] From a mechanistic perspective, PARP7 inhibitors and NAMPT inhibitors are somewhat complementary. PARP7 inhibition primarily enhances the innate immune response of tumor cells by restoring type I interferon-related signaling; NAMPT inhibition, on the other hand, blocks NAD+. + The salvage biosynthetic pathway weakens the metabolic adaptation capacity of tumor cells and may affect immunometabolic processes related to inflammatory responses, myeloid immunosuppressive cells, and the tumor immunosuppressive microenvironment. Simultaneous intervention in both pathways is expected to exert a synergistic effect at both the immunomodulatory and metabolic levels, thereby more comprehensively inhibiting tumor development and progression.

[0007] However, the combined use of PARP7 inhibitors and NAMPT inhibitors may still present challenges such as complex drug dosage ratios, inconsistent pharmacokinetic properties, varying in vivo exposure levels, different tissue distributions, increased risk of drug interactions, and poor clinical convenience, thus affecting the stable efficacy of dual-target inhibition. Therefore, developing a dual-target small molecule capable of acting on both PARP7 and NAMPT in a single chemical entity is of great significance for improving the synchronicity and controllability of dual-pathway intervention. Summary of the Invention

[0008] In view of this, the purpose of this invention is to provide pyridazinone derivatives, their preparation methods, and applications.

[0009] To achieve the above objectives, the present invention provides the following technical solution: This invention provides pyridazinone derivatives with dual PARP7 / NAMPT inhibitory activity, or their optical isomers, racemates, single enantiomers, possible diastereomers, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, or solvates, wherein the structures of the derivatives are shown in formula (I): In the formula for or “ "express The site linked to pyridazinone, "express The site connected to L; In the formula, L is a linking group connecting the PARP7-binding fragment and the NAMPT-binding fragment, selected from one of the following structural fragments: ; “ "express The site connected to L; " indicates the site where L and R are connected; In the formula, R is a structural fragment that can bind to the NAMPT active pocket and produce NAMPT inhibitory activity, and is selected from one of the following structural fragments; .

[0010] This invention also provides the application of the above-mentioned pyridazinone derivatives in the preparation of dual-target inhibitors of PARP7 and NAMPT.

[0011] The present invention also provides the use of the above-mentioned pyridazinone derivatives in the preparation of medicaments for the prevention and / or treatment of tumors.

[0012] Preferably, the tumor is selected from one or more of breast cancer, ovarian cancer, prostate cancer, colon cancer, gastric cancer, non-small cell lung cancer, glioma, kidney cancer, pancreatic cancer, liver cancer, melanoma, leukemia, and cervical cancer.

[0013] Preferably, the drug further comprises one or more other antitumor drugs, immunotherapy drugs, chemotherapy drugs or targeted therapy drugs, and the pyridazinone derivative is used in combination with the other drugs.

[0014] Preferably, the dosage form of the drug is tablets, capsules, granules, injections, lyophilized powder injections, liposome preparations, or nano-preparations.

[0015] Preferably, the drug is administered orally, intravenously, intramuscularly, subcutaneously, intraperitoneally, intratumorally, or locally.

[0016] It contains at least the following beneficial technical effects: (1) This invention provides pyridazinone derivatives, their preparation methods and applications, and provides a new structural type for the development of PARP7 / NAMPT dual-target anti-tumor drugs.

[0017] (2) The present invention integrates the PARP7 inhibition-related pyridazinone structure and the NAMPT inhibition-related structural fragment into the same molecule, which can act on both PARP7 and NAMPT targets simultaneously.

[0018] (3) Compared with single PARP7 inhibitors, the compounds of the present invention further introduce NAMPT inhibition, which can simultaneously intervene in tumor immune regulation and NAD. + Metabolic processes.

[0019] (4) Compared with single NAMPT inhibitors, the compounds of the present invention also have PARP7 inhibitory activity, which is beneficial to exert anti-tumor effects from multiple links.

[0020] (5) Compared with the combined administration of PARP7 inhibitors and NAMPT inhibitors, the present invention adopts a single small molecule dual-target inhibition strategy, which can avoid problems such as complex dosage ratios, inconsistent pharmacokinetics and increased risk of drug interactions in combined drug administration.

[0021] (6) This invention obtains pyridazinone derivatives with well-defined structures and feasible preparation methods through fragment assembly, linker optimization and structural modification strategies, which facilitates subsequent structure-activity relationship studies and candidate compound optimization.

[0022] (7) The representative compounds provided by the present invention have been verified by PARP7 enzyme activity inhibition experiment and NAMPT enzyme activity inhibition experiment, showing dual-target inhibitory activity.

[0023] (8) The representative compounds provided by this invention can reduce NAD in tumor cells. + It has a high level of activity and inhibits tumor cell proliferation, showing potential for further development into an anti-tumor drug candidate.

[0024] (9) The present invention also provides a method for preparing the pyridazinone derivative, a pharmaceutical composition thereof and its application in the preparation of antitumor drugs, which has good drug development value. Detailed Implementation

[0025] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0026] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0027] Unless otherwise specified, "room temperature" and "normal temperature" in this invention refer to 25±2℃.

[0028] Unless otherwise specified, all raw materials or instruments used in the following embodiments of the present invention are commercially available.

[0029] Preparation instructions for relevant raw materials and intermediates: The preparation method of C1-2 is as follows: At 25°C, 10.7 mmol of potassium carbonate was added to 100 mL of a solution of 5.37 mmol of 1-(tert-butyloxycarbonyl)piperazine and 5.37 mmol of 2-chloro-5-(methyl carboxylate)pyrimidine. The reaction mixture was stirred at 80°C for 1 hour. After the reaction was completed, the reaction solution was slowly poured into 500 mL of an ice-water mixture and filtered to obtain methyl 2-[4-(tert-butyloxycarbonyl)piperazin-1-yl]pyrimidine-5-carboxylate, i.e., C1-1. At 0 °C, 4 M HCl / ethyl acetate solution was slowly added to 1.50 mmol of C1-1, and the reaction mixture was stirred at 25 °C for 3 hours; the mixture was filtered to give methyl 2-(piperazin-1-yl)pyrimidine-5-carboxylic acid hydrochloride, i.e., C1-2.

[0030] The preparation method of A13 is as follows: Under nitrogen protection and at 0°C, 500 mL of a solution containing 157 mmol of 4,5-dibromopyridazine-3(2H)-one was added. In an N,N-dimethylformamide solution, 34.66 mmol of potassium iodide was added, followed by 315.1 mmol of sodium hydride in portions. The reaction mixture was stirred for 1 hour under nitrogen protection and at 0°C. Then, under nitrogen protection at 0°C, 217 mmol of (2-(chloromethoxy)ethyl)trimethylsilane was slowly added dropwise to the reaction mixture. The reaction mixture was stirred for 1 hour under nitrogen protection at 0°C. After the reaction was completed, the reaction mixture was slowly poured into a 2.5 L ice-water mixture. The mixture was extracted three times with 500 mL of ethyl acetate each time. The organic phase was collected, washed with 1 L of saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography with petroleum ether:ethyl acetate = 100:1 as the eluent to give 4-bromo-5-chloro-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazine-3(2H)-one, i.e., A-2. At room temperature, 142 mmol of potassium hydroxide was added in portions to a 300 mL methanol solution containing 123.97 mmol of A-2. The resulting solution was stirred at room temperature for 10 hours. After the reaction was completed, the reaction solution was evaporated to dryness. 500 mL of water was added to the crude product, and the product was extracted three times with 500 mL of ethyl acetate each time. The organic layers were combined, washed with 250 mL of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with ethyl acetate:petroleum ether = 1:2 as the eluent to obtain 4-bromo-5-methoxy-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazine-3(2H)-one, i.e., A-3. 89.8 mmol of A-3, 269.4 mmol of trifluoromethylating agent, and 44.9 mmol of cuprous iodide were added to 200 mL of N-methylpyrrolidone. The mixture was stirred at 100 °C for 12 hours. After the reaction was completed, the mixture was cooled and filtered. The reaction was quenched with 1000 mL of water and extracted three times with 1000 mL of ethyl acetate each time. The organic layers were combined, washed with 250 mL of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with dichloromethane:methanol = 40:1 as the eluent to obtain 5-methoxy-4-trifluoromethyl-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazine-3(2H)-one, i.e., A-5. At 20°C, 111.07 mmol of trimethyliodosilane was added dropwise to 200 mL of N,N-dimethylformamide solution containing 74.05 mmol of A-5. The resulting solution was stirred at 85°C for 10 hours. Then, 850 mL of water was added to quench the reaction. The solution was extracted three times with 500 mL of ethyl acetate each time. The organic layers were combined, washed with 250 mL of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with dichloromethane:methanol = 10:1 as the eluent to obtain 5-hydroxy-4-trifluoromethyl-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazine-3(2H)-one, i.e., A-6. At 0 °C, 185.7 mmol of oxaloyl chloride was added dropwise to 200 mL of N,N-dimethylformamide solution containing 61.9 mmol of A-6. The resulting solution was stirred at room temperature for 10 hours. Then, 200 mL of water was added to quench the reaction. The solution was extracted three times with 300 mL of ethyl acetate each time, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with ethyl acetate:petroleum ether = 1:50 as the eluent to obtain 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)one, i.e., A-7. At 25°C, 60.51 mmol of triethylamine and 60.51 mmol of (S)-2-aminopropane-1-ol were added to 100 mL of ethanol solution containing 50.46 mmol of A-7. The reaction mixture was stirred at 60°C for 1 hour. After the reaction was completed, the reaction solution was concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography with dichloromethane:methanol = 10:1 to 5:1 as the eluent to obtain (S)-5-((1-hydroxypropyl-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazine-3(2H)-one, i.e., A-9. 43.54 mmol of A-9 was dissolved in 100 mL of acetonitrile, and 435.4 mmol of methyl acrylate and 43.54 mmol of cesium carbonate were added. The mixture was reacted at room temperature for 4 hours. The reaction mixture was evaporated to dryness, diluted with 100 mL of water, and extracted twice with 100 mL of ethyl acetate each time. The organic layers were combined and washed three times with 100 mL of saturated brine each time. The mixture was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by silica gel column chromatography with dichloromethane:methanol = 40:1 as the eluent to obtain methyl (S)-3-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionate, i.e., A-11. 26.48 mmol of A-11 was dissolved in 25 mL of dichloromethane, 5 mL of trifluoroacetic acid was added, and the mixture was reacted at room temperature for 4 hours. The reaction mixture was then evaporated to dryness to give methyl (S)-3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionate, i.e., A-12. 21.66 mmol of A-12 was dissolved in a mixed solvent of 30 mL methanol and 5 mL water, and 216.6 mmol of lithium hydroxide monohydrate was added. The mixture was reacted at room temperature for 2 hours. The reaction mixture was evaporated to dryness, 30 mL of water was added, and the pH was adjusted to 3 with 1 M hydrochloric acid. The mixture was extracted three times with 30 mL of ethyl acetate each time. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain (S)-3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionic acid, i.e., A-13.

[0031] The preparation method of A-15 is as follows: 16.8 mmol of A-13 was dissolved in N,N-dimethylformamide, and 84 mmol of triethylamine and 22.6 mmol of 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate were added. After reacting at room temperature for 0.5 hours, 16.8 mmol of 2-(piperazin-1-yl)pyrimidin-5-carboxylic acid methyl ester hydrochloride C1-2 was added, and the reaction was carried out overnight at room temperature. After the reaction was completed, the reaction solution was slowly poured into 50 mL of ice-water mixture and extracted three times with 10 mL of ethyl acetate each time. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography with dichloromethane:methanol = 10:1 as the eluent to obtain (S)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidin-5-carboxylic acid methyl ester, i.e., A-14. Step 10: Dissolve 6.04 mmol of (S)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidine-5-carboxylic acid methyl ester (A-14) in a mixed solvent of 30 mL methanol and 5 mL water. Add 60.4 mmol of lithium hydroxide monohydrate and react at room temperature for 2 hours. Rotate the reaction mixture to dryness, add 30 mL water, adjust the pH to 3 with 1 M hydrochloric acid, and extract three times with 30 mL of ethyl acetate each time. Combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to obtain (S)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidine-5-carboxylic acid, i.e., A-15.

[0032] Preparation of intermediate B1-2: In the first step, 4.4 mmol of (E)-3-(pyridin-3-yl)acrylic acid (B1) was dissolved in N,N-dimethylformamide, and 3.7 mmol of triethylamine and 7.4 mmol of 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate were added. After reacting at room temperature for 0.5 hours, 3.7 mmol of 1-N-BOC-4-(4-aminobutyl)piperidine hydrochloride was added, and the reaction was carried out overnight at room temperature. After the reaction was completed, the reaction solution was slowly poured into 50 mL of ice-water mixture, extracted three times with 10 mL of ethyl acetate each time, and the organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography with dichloromethane:methanol = 20:1 as the eluent to obtain (E)-4-(4-(3-(pyridin-3-yl)acrylamido)butyl)piperidine-1-carboxylic acid tert-butyl ester (B1-1). In the second step, at 0°C, 4M HCl / ethyl acetate solution was slowly added to 1.50 mmol of B1-1, and the reaction mixture was stirred at 25°C for 3 hours; the mixture was then filtered to obtain (E)-N-(4-(piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide hydrochloride (B1-2).

[0033] Preparation of intermediate B2-2: Following the preparation method of intermediate B1-2, 1-N-BOC-4-(4-aminobutyl)piperidine hydrochloride was replaced with BOC-1,4-butanediamine hydrochloride to obtain the final product.

[0034] Preparation of intermediate B3-2: Following the preparation method of intermediate B1-2, 1-N-BOC-4-(4-aminobutyl)piperidine hydrochloride was replaced with N-(5-aminopentyl)carbamate tert-butyl ester to obtain the final product.

[0035] Preparation of intermediate B4-2: Following the preparation method of intermediate B1-2, 1-N-BOC-4-(4-aminobutyl)piperidine hydrochloride was replaced with N-(6-aminohexyl)carbamate tert-butyl ester to obtain the final product.

[0036] Preparation of intermediate B5-2: Following the preparation method of intermediate B1-2, 1-N-BOC-4-(4-aminobutyl)piperidine hydrochloride was replaced with [2-(2-aminoethoxy)ethyl]carbamate tert-butyl ester to obtain the product.

[0037] Preparation of intermediate B6-2: Following the preparation method of intermediate B1-2, 1-N-BOC-4-(4-aminobutyl)piperidine hydrochloride was replaced with [2-(2-aminoethoxy)ethyl]carbamate tert-butyl ester to obtain the product.

[0038] Preparation of intermediate B7-2: Following the preparation method of intermediate B1-2, 1-N-BOC-4-(4-aminobutyl)piperidine hydrochloride was replaced with 4-(3-aminopropyl)piperazine-1-carboxylic acid tert-butyl ester to obtain the final product.

[0039] Preparation of intermediate B8-1: 3.35 mmol of (E)-3-(pyridin-3-yl)acrylic acid (B1) was dissolved in N,N-dimethylformamide, followed by the addition of 3.35 mmol of triethylamine and 6.72 mmol of 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate. After reacting at room temperature for 0.5 hours, 16.75 mmol of 2-(4-aminophenyl)ethylamine was added, and the reaction was allowed to proceed overnight at room temperature. After the reaction was complete, the reaction solution was slowly poured into a 50 mL ice-water mixture and extracted three times with 10 mL of ethyl acetate each time. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography with dichloromethane:methanol = 20:1 as the eluent to obtain (E)-N-(4-aminophenylethyl)-3-(pyridin-3-yl)acrylamide (B8-1).

[0040] Preparation of intermediate B9-2: Following the preparation method of intermediate B1-2, 1-N-BOC-4-(4-aminobutyl)piperidine hydrochloride was replaced with N-BOC-4-(3-aminopropyl)piperidine to obtain the final product.

[0041] Preparation of intermediate C2-4: Step 1: At 25°C, 66.4 mmol of pyridine was added to 100 mL of a solution of 5.6 mmol of p-nitrobenzenesulfonyl chloride and 5.6 mmol of piperazine-1-carboxylate tert-butyl ester (N-methylpyrrolidone). The reaction mixture was stirred at 80°C for 1 hour. After the reaction was completed, the reaction solution was slowly poured into 50 mL of an ice-water mixture and extracted three times with 10 mL of ethyl acetate each time. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography with petroleum ether:ethyl acetate = 10:1 as the eluent to obtain 4-((4-nitrophenyl)sulfonyl)piperazine-1-carboxylate tert-butyl ester (C2-1). In the second step, 2.89 mmol of C2-1 was dissolved in methanol, Pd / C was added, and the reaction was carried out under a hydrogen atmosphere for 2 hours. After the reaction was completed, the mixture was filtered and the filtrate was concentrated under reduced pressure to obtain tert-butyl 4-((4-aminophenyl)sulfonyl)piperazine-1-carboxylate (C2-2). Thirdly, at 0°C, 1.12 mmol of triphosgene and 1.12 mmol of triethylamine were added to a dichloromethane solution of 2.8 mmol of C2-2 and 2.8 mmol of 3-aminomethylpyridine. After the reaction was completed, the solution was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with dichloromethane:methanol = 40:1 as the eluent to obtain 4-((4-(3-(pyridin-3-ylmethyl)ureido)phenyl)sulfonyl)piperazine-1-carboxylic acid tert-butyl ester (C2-3). Fourth, at 0°C, 4M HCl / ethyl acetate solution was slowly added to 2.35 mmol of C2-3, and the reaction mixture was stirred at 25°C for 3 hours; the mixture was then filtered to give 1-(4-(piperazin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea hydrochloride (C2-4).

[0042] Preparation of intermediate C3-4: Following the preparation method of intermediate C2-4, triphosgene in the third step was replaced with thiophosgene to obtain 1-(4-(piperazin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea hydrochloride (C3-4).

[0043] Preparation of intermediate C4-4: Referring to the preparation method of intermediate C2-4, piperazine-1-carboxylic acid tert-butyl ester in the first step is replaced with piperidine-4-amine to obtain 1-(4-((4-aminopiperidin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea hydrochloride (C4-4).

[0044] Preparation of intermediate C5-4: Referring to the preparation method of intermediate C2-4, piperazine-1-carboxylic acid tert-butyl ester in the first step was replaced with 2,7-diazaspiro[4.4]nonane-2-carboxylic acid tert-butyl ester, and triphosgene in the third step was replaced with thiophosgene, thus obtaining 1-(4-((2,7-diazaspiro[4.4]non-2-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea hydrochloride (C5-4).

[0045] Preparation of intermediate C6-4: Following the preparation method of intermediate C2-4, replace 4-((4-aminophenyl)sulfonyl)piperazine-1-carboxylic acid tert-butyl ester in the first step with 4-(4-aminobutyl)piperidine-1-carboxylic acid tert-butyl ester to obtain 1-(4-(piperidine-4-yl)butyl)-3-(pyridin-3-ylmethyl)urea hydrochloride (C6-4).

[0046] Preparation of intermediate D1-2: Following the preparation method of intermediate B1-2, replace (E)-3-(pyridin-3-yl)acrylic acid in the first step with 5-azaindole-2-carboxylic acid to obtain the final product.

[0047] Preparation of intermediate D2-2: Following the preparation method of intermediate B1-2, replace (E)-3-(pyridin-3-yl)acrylic acid in the first step with imidazole[1,2-a]pyridin-6-carboxylic acid to obtain the final product.

[0048] Preparation of intermediate E1-4: First, at 0°C, 10.62 mmol of 4-aminopyridine was added to a 12.76 mmol sodium hydride solution of N,N-dimethylformamide. After reacting at room temperature for 30 minutes, a 10.62 mmol N,N-dimethylformamide solution of N-cyanoimino-S,S-dithiocarbonate was added, and the reaction was carried out overnight at room temperature. After the reaction was completed, the product was extracted three times with petroleum ether, 10 mL each time. The aqueous phase was adjusted to pH 8 with glacial acetic acid at 0°C and extracted three times with dichloromethane, 10 mL each time. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography with dichloromethane:methanol = 20:1 as the eluent to obtain (Z)-N'-cyano-N-(pyridin-4-yl)aminoformamide methyl thioformate (E1-2). In the second step, 1.56 mmol of E1-2 and 1.56 mmol of mono-BOC-pentanediamine were dissolved in 10 mL of pyridine, and 3.12 mmol of triethylamine and 0.16 mmol of 4-dimethylaminopyridine were added. The mixture was reacted at 80 °C for 12 hours. After the reaction was completed, the mixture was concentrated under reduced pressure and extracted three times with 10 mL of petroleum ether each time. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography with dichloromethane:methanol = 20:1 as the eluent to obtain (E)-(5-(2-cyano-3-(pyridin-4-yl)guanidinyl)pentyl)carbamate tert-butyl ester (E1-3). Third, at 0°C, 4M HCl / ethyl acetate solution was slowly added to 0.86 mmol of E1-3, and the reaction mixture was stirred at 25°C for 3 hours; the mixture was then filtered to obtain (E)-1-(5-aminopentyl)-2-cyano-3-(pyridin-4-yl)guanidine (E1-4).

[0049] Preparation of intermediate E2-4: Referring to the preparation method of intermediate E1-4, the mono-BOC-pentanediamine in the second step was replaced with N-(6-aminohexyl)carbamate tert-butyl ester, thus obtaining (E)-1-(7-aminoheptyl)-2-cyano-3-(pyridin-4-yl)guanidine hydrochloride.

[0050] Preparation of intermediate E3-4: Referring to the preparation method of intermediate E1-4, the mono-BOC-pentanediamine in the second step is replaced with 1-tert-butoxycarbonyl-1,7-diaminoheptane to obtain (E)-1-(6-aminohexyl)-2-cyano-3-(pyridin-4-yl)guanidine hydrochloride.

[0051] Example 1 Preparation of (S,E)-N-(4-(1-(2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidin-5-carbonyl)piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide (compound 1) first step: (S)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidin-5-carboxylic acid (A-15) (0.2 g, 0.4 mmol) was dissolved in DMF, followed by the addition of triethylamine (0.2 g, 2 mmol) and 1H-benzotriazol-1-yloxotripyrrolidinyl hexafluorophosphate (0.41 g, 0.8 mmol). After reacting at room temperature for 0.5 h, (E)-N-(4-(piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide hydrochloride (B1-2) was added. (0.129 g, 0.4 mmol) was reacted overnight at room temperature. After the reaction was complete, the reaction solution was slowly poured into a 50 mL ice-water mixture. The reaction solution was extracted with ethyl acetate (10 mL × 3). The organic phase was collected, filtered with anhydrous Na2SO4, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (dichloromethane:methanol = 10:1) to give a light white solid compound (S)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidine-5-carboxylic acid methyl ester (compound 1) (0.12 g, yield 40%).

[0052] 1 H NMR (400 MHz, DMSO) δ 12.45 (s, 1H), 8.75 (d, J = 2.2 Hz, 1H), 8.54 (dd, J = 4.8, 1.6 Hz, 1H), 8.44 (s, 1H), 8.15 (t, J = 5.7 Hz, 1H), 7.97 (dt, J =8.0, 2.0 Hz, 1H), 7.91 (s, 1H), 7.48 – 7.40 (m, 2H), 6.72 (d, J = 15.9 Hz, 1H), 6.27 (dd, J= 8.5, 4.2 Hz, 1H), 4.19 – 4.11 (m, 1H), 3.81 – 3.73 (m, 4H), 3.72 – 3.66 (m, 2H), 3.56 – 3.51 (m, 4H), 3.49 (d, J = 5.6 Hz, 2H), 3.18 (q, J = 6.6Hz, 1H), 2.59 (t, J = 6.5 Hz, 1H), 1.69 (d, J = 12.7 Hz, 2H), 1.56 – 1.40 (m,2H), 1.25 (s, 4H), 1.15 (d, J = 6.5 Hz, 3H), 1.11 – 1.02 (m, 2H), 0.90 – 0.77 (m, 3H). Example 2 Preparation of (S)-1-(4-(4-(3-(2-(6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (compound 19) first step: (S)-3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionic acid (A-13) (0.2 g, 0.4 mmol) was dissolved in DMF, and triethylamine (0.2 g, 2 mmol) and 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (0.41 g, 0.8 mmol) were added. The mixture was reacted at room temperature for 0.5 h, and then 1-(4-(piperazin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea hydrochloride (C3-4) (0.17 g, 0.4 mmol) was added. The mixture was reacted at room temperature overnight. After the reaction was completed, the reaction solution was slowly poured into a 50 mL ice-water mixture. The reaction solution was extracted with ethyl acetate (10 mL × 3), and the organic phase was collected, filtered with anhydrous Na2SO4, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (dichloromethane:methanol = 20:1) to give a light white solid compound (S)-1-(4-(4-(3-(2-(6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)sulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea (compound 19) (0.10 g, yield 37%).

[0053] 1H NMR (400 MHz, DMSO) δ 12.46 (s, 1H), 9.33 (s, 1H), 7.89 – 7.79 (m,2H), 7.67 – 7.54 (m, 6H), 7.00 (s, 1H), 6.24 – 6.18 (m, 1H), 4.37 (s, 2H),4.10 – 4.06 (m, 1H), 3.50 (t, J = 32.9 Hz, 10H), 2.81 (d, J = 14.2 Hz, 6H), 1.10(d, J = 6.5 Hz, 3H). 13 C NMR (101 MHz, DMSO) δ 169.16, 158.35, 155.30, 145.50, 136.41,129.33, 127.71 (d, J = 264.1 Hz), 125.30 (d, J = 272.6 Hz), 117.70, 95.98 (d, J =27.6 Hz), 73.79, 67.28, 48.88, 46.51, 46.21, 44.63, 40.99, 32.89, 17.97. Example 3 Preparation of (S,E)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)-N-(4-(-3-(pyridin-3-yl)acrylamido)phenethyl)pyrimidin-5-carboxamide (compound 25) Step 1: Synthesis of (S)-N-(4-aminophenylethyl)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidin-5-carboxamide (A-16) (S)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidin-5-carboxylic acid (A-15) (0.5 g, 1.0 mmol) was dissolved in DMF, and triethylamine (0.50 g, 5 mmol) and 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (1.0 g, 2.0 mmol) were added. The mixture was reacted at room temperature for 0.5 h, and then 2-(4-aminophenyl)ethylamine (0.136 g, 1.0 mmol) was added. The mixture was reacted at room temperature overnight. After the reaction was completed, the reaction solution was slowly poured into a 50 mL ice-water mixture. The reaction solution was extracted with ethyl acetate (10 mL × 3), and the organic phase was collected, filtered with anhydrous Na2SO4, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (dichloromethane:methanol = 10:1) to give a light white solid compound (S)-N-(4-aminophenylethyl)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidin-5-carboxamide (A-16) (0.22 g, yield 36%).

[0054] Step 2: Synthesis of (S,E)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)-N-(4-(-3-(pyridin-3-yl)acrylamido)phenethyl)pyrimidin-5-carboxamide (compound 25) (S)-N-(4-aminophenylethyl)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidin-5-carboxamide (A-15) (0.22 g, 0.35 mmol) was dissolved in DMF, and triethylamine (0.18 g, 1.78 mmol) and 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate (0.25 g, 0.7 mmol) were added. The mixture was reacted at room temperature for 0.5 h, and then (E)-3-(pyridin-3-yl)acrylic acid (0.052 g, 0.35 mmol) was added. The mixture was reacted at room temperature overnight. After the reaction was completed, the reaction solution was slowly poured into a 50 mL ice-water mixture. The reaction solution was extracted with ethyl acetate (10 mL × 3), and the organic phase was collected, filtered with anhydrous Na2SO4, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (dichloromethane:methanol = 10:1) to give a white solid compound (S,E)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)-N-(4-(-3-(pyridin-3-yl)acrylamido)phenethyl)pyrimidin-5-carboxamide (compound 25) (0.104 g, yield 39%).

[0055] 1 H NMR (400 MHz, DMSO) δ 12.45 (s, 1H), 10.24 (s, 1H), 8.83 – 8.74(m, 3H), 8.59 (s, 1H), 8.46 (s, 1H), 7.91 (s, 1H), 7.63 (s, 3H), 7.49 (s,1H), 7.20 (d, J = 8.0 Hz, 2H), 6.93 (d, J = 15.9 Hz, 1H), 6.28 (s, 1H), 4.15 (s,1H), 3.92 – 3.75 (m, 4H), 3.69 (s, 1H), 3.55 – 3.47 (m, 5H), 3.38 (s, 3H), 2.80 (s, 2H), 2.59 (s, 2H), 1.16 (s, 3H). 13C NMR (101 MHz, DMSO) δ 169.35, 163.90, 163.39, 161.81, 158.35,158.00, 150.75, 149.65, 146.57, 137.76, 137.08, 135.10, 134.64, 131.08,129.51, 129.07, 125.33 (d, J = 272.8 Hz), 124.82, 124.56, 119.81, 116.99, 95.97(d, J = 27.7 Hz), 73.90, 67.44, 48.97, 45.03, 44.04, 43.68, 41.14, 40.46,35.15, 33.20, 18.01. Following the synthetic method of Example 1, the compounds of the following examples were synthesized by replacing (E)-N-(4-(piperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide hydrochloride (B1-2) with different intermediates.

[0056] Table 1 Referring to the synthesis method of Example 2, the following compound examples were synthesized by replacing 1-(4-(piperazin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)thiourea hydrochloride (C3-4) with different intermediates.

[0057] Table 2 Experimental Example 1 Antitumor activity test The inhibitory activity of the compound against cancer cells was detected using the MTT assay, also known as the MTT colorimetric assay, a method for detecting cell viability and growth. MTT (yellow succinyl sulfoxide) can penetrate the cell membrane and enter the cell. Succinate dehydrogenase in the mitochondria of living cells reduces exogenous MWTT to water-insoluble, blue-purple needle-like formazan crystals, which are then deposited in the cells. These crystals are soluble in dimethyl sulfoxide (IMSO). The absorbance at 570 nm using an enzyme-linked immunosorbent assay (ELISA) reader indirectly reflects the number of viable cells. The cancer cell lines used were CT26 (mouse colon cancer cells) and NCI-1373 (human lung adenocarcinoma cells). The specific experimental results are shown in the table below: (1) Collect cells in the logarithmic growth phase, adjust the cell suspension concentration, and add 100 μL of cell suspension to each well of a 96-well plate; the number of cells per well is approximately 2000. Incubate overnight at 37°C with 5% CO2 until the cells are completely adhered. (2) Set up drug concentration gradients, with 3 replicates for each concentration gradient. Dilute the drug to the corresponding culture medium to the desired final concentration. Remove the original culture medium from the 96-well plate and add 100 μL of the prepared culture medium containing the desired final drug concentration. Incubate at 5% CO2. 2, Incubate at 37°C: Simultaneously set up a blank group (containing only 100 μL of culture medium, without cells; subsequent treatment was the same as other wells) and a control group (containing cells and culture medium): (3) Add 100 μL MTT solution (5 mg / mL) to each well after drug treatment to 6t, and continue culturing for 4h (the total drug treatment period for cells is 6 days). (4) Aspirate the culture medium from the wells (if the cells are suspended, centrifuge at 2500 rpm for 5 min before aspirating the culture medium). Add 150 μL of dimethyl sulfoxide to each well and shake until the solids are fully dissolved. Measure the absorbance of each well at 0D570 nm using a microplate reader. (5) Calculate the inhibition rate: Inhibition rate = 1 - (OD value of the drug-treated group - OD value of the blank group) / (OD value of the control group - OD value of the blank group) = (OD value of the control group - OD value of the drug-treated group) / (OD value of the control group - OD value of the blank group) (6) Repeat the above experimental steps three times, obtain the average of the three inhibition rates, and use IC50 to calculate the average value. 50 The calculator calculates the IC of the drug. 50 value.

[0058] The specific experimental results are shown in Table 3 below: The compounds in the examples have good anti-proliferative activity against a variety of tumor cells (IC50). 50 μM) The antiproliferative activity results of the compounds in each example are shown in Table 3 below. Among them, IC... 50Values ​​are defined using the following symbols: "+" indicates IC 50 <0.1 μM; "++" indicates IC 50 ≥ 0.1 μM and < 1.0 μM; "++" indicates IC 50 ≥ 1.0 μM and <10.0 μM; "++++" indicates IC 50 ≥ 10.0 μM.

[0059] Table 3 Experiment Example 2 Determination of the inhibitory activity of the compound against PARP7 enzyme The inhibitory effect of the compounds of this invention on PARP7 enzyme activity was determined by ELISA / luminescence assay. The test compounds were prepared into a 10 mM stock solution using DMSO and diluted to the required test concentration before the experiment. RBN-2397 was used as a positive control, and DMSO was used as a solvent control.

[0060] I. Determination of single-concentration inhibition rate of PARP7 (1) Take 10mM MDMSO stock solutions of compounds 1-25 to be tested, and dilute them with DMSO-containing diluent as needed to prepare working solutions. For single-concentration screening, the final concentration of the test compound is 0.1μM. The final concentration of DMSO in all test wells should be consistent.

[0061] (2) Dilute histones to 20 μg / mL with PBS buffer and add 100 μL to each well. Incubate the 96-well plate at 4°C overnight to allow histones to coat the surface of the 96-well plate.

[0062] (3) After adding the coating solution, add NAD-containing solution to each well. + Biotin-labeled NAD + The reaction system with activated DNA. The reaction buffer consisted of 50 mM Tris, 2 mM MgCl2, and pH 8.0.

[0063] (4) Add 5 μL of the working solution of the test compound to the corresponding well to make the final concentration of the test compound 0.1 μM. Add an equal volume of DMSO diluent to the solvent control well. Set up two replicates for each compound.

[0064] (5) Add PARP7 enzyme solution to each well to start the reaction. Incubate the reaction system at 30°C for 1 hour.

[0065] (6) After the enzyme reaction is complete, add streptavidin-labeled HRP solution to each well and incubate at 30°C for 30 min.

[0066] (7) Add 0.1M citrate buffer containing H2O2 and luminol to each well, pH 5.4, and use a multi-functional microplate reader to detect the luminescence signal.

[0067] (8) Using the luminescence signal of the solvent control well as the control value, the PARP7 inhibition rate was calculated according to the following formula: PARP7 inhibition rate (%) = (Lucontrol - Lutreated) / Lucontrol × 100%; where Lucontrol is the luminescence signal of the solvent control well and Lutreated is the luminescence signal of the well treated with the analyte.

[0068] II. PARP7 IC 50 Measurement (1) Based on the screening results of single concentration inhibition rate of PARP7, representative compounds 1, 5, 9 and 21 were selected for PARP7 IC50 assay. 50 Determination. RBN-2397 was used as a positive control.

[0069] (2) The 10 mM MDS-21 stock solutions of compounds 1, 5, 9 and 21 were serially diluted to final concentrations of 0.1 nM, 0.33 nM, 1 nM, 3.3 nM, 10 nM, 33 nM, 100 nM, 333 nM and 1 μM. The positive control RBN-2397 was set to final concentrations of 0.01 nM, 0.03 nM, 0.1 nM, 0.33 nM, 1 nM, 3.3 nM, 10 nM, 33 nM and 100 nM.

[0070] (3) Following the method in the PARP7 single concentration inhibition rate determination, 96-well plates were coated with 20 μg / mL histone and incubated overnight at 4°C.

[0071] (4) After discarding the coating solution, add NAD-containing solution to each well. + Biotin-labeled NAD + Add 5 μL of the test compound or solvent at different concentrations to the reaction system with activated DNA. Two replicates are set for each concentration.

[0072] (5) Add PARP7 enzyme solution to each well to start the reaction and incubate at 30°C for 1 hour.

[0073] (6) After the reaction was completed, streptavidin-labeled HRP solution was added and incubated at 30°C for 30 min. Then, citrate buffer containing H2O2 and luminol was added, and the luminescence signal was detected.

[0074] (7) Calculate the PARP7 enzyme activity or inhibition rate based on the luminescence signals at different concentrations. Plot the logarithm of the compound concentration on the x-axis and the enzyme activity or inhibition rate on the y-axis, and use GraphPadPrism software for nonlinear regression fitting to calculate IC50. 50 Values. Results are expressed as the average of two replicate experiments, as shown in Table 4.

[0075] Experimental Example 3 Determination of the inhibitory activity of the compound against NAMPT enzyme The inhibitory effect of the compounds of this invention on NAMPT enzyme activity was determined by fluorescence assay. The test compounds were prepared into a 10 mM stock solution using DMSO, and then diluted 10 times with 10% DMSO to a final working solution before the experiment. FK866 was used as a positive control, and DMSO was used as a solvent control.

[0076] I. Determination of single-concentration inhibition rate of NAMPT (1) Take 10mM MDMSO stock solution of the test compounds 1-25 and dilute it with 10% DMSO to prepare a working solution of the compound with a final concentration 10 times higher. For single concentration screening, the final concentration of the test compound is 0.1μM.

[0077] (2) Add 5 μL of the compound working solution to the reaction wells. The total reaction volume is 50 μL, so that the final concentration of DMSO in the reaction system is 1%. Add an equal volume of 10% DMSO to the solvent control wells. Set up two duplicate wells for each compound.

[0078] (3) Add NAMPT enzyme and reaction components to each well to make the final reaction system contain 50 mM Tris-HCl, 12.5 mM MgCl2, 20 μM nICotinamide, 0.4 mM phosphoribosyl pyrophosphate, mM ATP, 30 μg / mL alcohol dehydrogenase, 1 μg / mL NMNAT, 1.5% alcohol, 1 mM DTT, 0.02% BSA, 0.01% Tween 20 and the analyte, with a pH of 8.0. The amount of NAMPT enzyme used is 200 ng, and the reaction substrates are 20 μM nICotinamide and 400 μM phosphoribosyl pyrophosphate.

[0079] (4) Set up reaction wells without the test compound as 100% enzyme activity control, denoted as Ft; set up reaction wells without NAMPT enzyme as background wells, denoted as Fb.

[0080] (5) Incubate the reaction system at 30°C for 90 min.

[0081] (6) After the reaction, the fluorescence signal was detected by a multi-functional microplate reader with an excitation wavelength of 360 nm and an emission wavelength of 460 nm.

[0082] (7) Calculate NAMPT enzyme activity according to the following formula: NAMPT enzyme activity (%) = (F - Fb) / (Ft - Fb) × 100% Where F represents the fluorescence signal after the addition of the test compound, Ft represents the fluorescence signal without the addition of the test compound, and Fb represents the background fluorescence signal without the addition of NAMPT enzyme.

[0083] (8) Calculate the NAMPT inhibition rate according to the following formula: NAMPT inhibition rate (%) = 100% - NAMPT enzyme activity (%) II. NAMPT IC 50 Measurement (1) Based on the NAMPT single-concentration inhibition rate screening results and combined with the PARP7 inhibition activity results, representative compounds 1, 5, 9 and 21 were selected for NAMPT IC50 assay. 50 Determination. FK866 was used as a positive control.

[0084] (2) The 10 mM DMSO stock solutions of compounds 1, 5, 9 and 21 were serially diluted with 10% DMSO to set final concentrations of 1 nM, 3.3 nM, 10 nM, 33 nM, 100 nM, 333 nM, 1 μM, 3.3 μM and 10 μM. The positive control FK866 was set to final concentrations of 0.1 nM, 0.33 nM, 1 nM, 3.3 nM, 10 nM, 33 nM, 100 nM, 333 nM and 1 μM.

[0085] (3) Add 5 μL of compound working solution or DMSO solvent of different concentrations to each reaction well as a control. Two replicates are set for each concentration.

[0086] (4) Adding the NAMPT reaction system: Add NAMPT enzyme and reaction components to each well, so that the final 50 μL reaction system contains 50 mM Tris-HCl, 12.5 mM MgCl2, 20 μM nICotinamide, 0.4 mM phosphoribosylpyrophosphate, 2 mM ATP, 30 μg / mL alcoholde hydrogenase, 10 μg / mL NMNAT, 1.5% alcohol, 1 mM MTT, 0.02% BSA, 0.01% Tween 20 and the analyte, with a pH of 8.0. The final concentration of DMSO in the reaction system is maintained at 1%.

[0087] (5) Set up reaction wells without the compound as 100% enzyme activity control and set up reaction wells without NAMPT enzyme as background wells.

[0088] (6) Incubate the reaction system at 30°C for 90 min.

[0089] (7) After the reaction is complete, the fluorescence signal is detected. The excitation wavelength is 360 nm and the emission wavelength is 460 nm.

[0090] (8) Calculate NAMPT enzyme activity and inhibition rate based on fluorescence signals at each concentration. Plot the logarithm of compound concentration on the x-axis and NAMPT enzyme activity or inhibition rate on the y-axis, and use GraphPadPrism software for nonlinear regression fitting to calculate IC50. 50 Values. Results are expressed as the average of two replicate experiments, as shown in Table 4.

[0091] Table 4. Enzyme inhibitory activities of the target compounds against PARP7 and NAMPT. Note “—” indicates that the measurement was not performed. The above description is only a preferred embodiment of the present invention. It should be noted that those skilled in the art can make several improvements and modifications without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A pyridazinone derivative having dual PARP7 / NAMPT inhibitory activity, or its optical isomer, racemate, single enantiomer, possible diastereomer, or pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, or solvate, wherein the structure of the derivative is shown in formula (I): In the formula for or " "express The site where pyridazinone is attached, "express The site connected to L; In the formula, L is a linking group connecting the PARP7-binding fragment and the NAMPT-binding fragment, selected from one of the following structural fragments: ; " "express The site connected to L; " indicates the site where L and R are connected; In the formula, R is a structural fragment that can bind to the NAMPT active pocket and produce NAMPT inhibitory activity, and is selected from one of the following structural fragments; 。 2. The pyridazinone derivative according to claim 1, characterized in that, Any one of compounds 1 to 25 with the following structures: 。 3. The method for preparing the pyridazinone derivative according to claim 1, characterized in that, The following synthetic routes are included: when for At that time, synthetic route one was adopted: when for At that time, synthetic route two was adopted; 。 4. The preparation method according to claim 3, characterized in that, The specific method of the first synthetic route is as follows: S1. Preparation of A13: Under nitrogen protection and at 0°C, 500 mL of a solution containing 157 mmol of 4,5-dibromopyridazine-3(2H)-one was added. In an N,N-dimethylformamide solution, 34.66 mmol of potassium iodide was added, followed by 315.1 mmol of sodium hydride in portions. The reaction mixture was stirred for 1 hour under nitrogen protection and at 0°C. Then, under nitrogen protection at 0°C, 217 mmol of (2-(chloromethoxy)ethyl)trimethylsilane was slowly added dropwise to the reaction solution. The reaction mixture was stirred for 1 hour under nitrogen protection at 0°C. After the reaction was completed, the reaction solution was slowly poured into a 2.5 L ice-water mixture. The mixture was extracted three times with 500 mL of ethyl acetate each time. The organic phase was collected, washed with 1 L of saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel chromatography with petroleum ether:ethyl acetate = (110-100):1 as the eluent to obtain 4-bromo-5-chloro-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazine-3(2H)-one, i.e., A-2. At room temperature, 142 mmol of potassium hydroxide was added in portions to a 300 mL methanol solution containing 123.97 mmol of A-2. The resulting solution was stirred at room temperature for 10 hours. After the reaction was completed, the reaction solution was evaporated to dryness. 500 mL of water was added to the crude product, and the product was extracted three times with 500 mL of ethyl acetate each time. The organic layers were combined, washed with 250 mL of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with ethyl acetate:petroleum ether = 1:2 as the eluent to obtain 4-bromo-5-methoxy-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazine-3(2H)-one, i.e., A-3. 89.8 mmol of A-3, 269.4 mmol of trifluoromethylating agent, and 44.9 mmol of cuprous iodide were added to 200 mL of N-methylpyrrolidone. The mixture was stirred at 100 °C for 12 hours. After the reaction was completed, the mixture was cooled and filtered. The reaction was quenched with 1000 mL of water and extracted three times with 1000 mL of ethyl acetate each time. The organic layers were combined, washed with 250 mL of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with dichloromethane:methanol = 40:1 as the eluent to obtain 5-methoxy-4-trifluoromethyl-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazine-3(2H)-one, i.e., A-5. At 20°C, 111.07 mmol of trimethyliodosilane was added dropwise to 200 mL of N,N-dimethylformamide solution containing 74.05 mmol of A-5. The resulting solution was stirred at 85°C for 10 hours. Then, 850 mL of water was added to quench the reaction. The solution was extracted three times with 500 mL of ethyl acetate each time. The organic layers were combined, washed with 250 mL of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with dichloromethane:methanol = 10:1 as the eluent to obtain 5-hydroxy-4-trifluoromethyl-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazine-3(2H)-one, i.e., A-6. At 0–5 °C, 185.7 mmol of oxaloyl chloride was added dropwise to 200 mL of N,N-dimethylformamide solution containing 61.9 mmol of A-6. The resulting solution was stirred at room temperature for 10 hours. Then, 200 mL of water was added to quench the reaction. The solution was extracted three times with 300 mL of ethyl acetate each time, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with ethyl acetate:petroleum ether = 1:50 as the eluent to obtain 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)one, i.e., A-7. At 25°C, 60.51 mmol of triethylamine and 60.51 mmol of (S)-2-aminopropane-1-ol were added to 100 mL of ethanol solution containing 50.46 mmol of A-7. The reaction mixture was stirred at 60°C for 1 hour. After the reaction was completed, the reaction solution was concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography with dichloromethane:methanol = 10:1 to 5:1 as the eluent to obtain (S)-5-((1-hydroxypropyl-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazine-3(2H)-one, i.e., A-9. 43.54 mmol of A-9 was dissolved in 100 mL of acetonitrile, and 435.4 mmol of methyl acrylate and 43.54 mmol of cesium carbonate were added. The mixture was reacted at room temperature for 4 hours. The reaction mixture was evaporated to dryness, diluted with 100 mL of water, and extracted twice with 100 mL of ethyl acetate each time. The organic layers were combined and washed three times with 100 mL of saturated brine each time. The mixture was dried over anhydrous sodium sulfate and concentrated. The crude product was purified by silica gel column chromatography with dichloromethane:methanol = 40:1 as the eluent to obtain methyl (S)-3-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionate, i.e., A-11. 26.48 mmol of A-11 was dissolved in 25 mL of dichloromethane, 5 mL of trifluoroacetic acid was added, and the mixture was reacted at room temperature for 4 hours. The reaction mixture was then evaporated to dryness to give methyl (S)-3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionate, i.e., A-12. 21.66 mmol of A-12 was dissolved in a mixed solvent of 30 mL methanol and 5 mL water, and 216.6 mmol of lithium hydroxide monohydrate was added. The mixture was reacted at room temperature for 2 hours. The reaction mixture was evaporated to dryness, 30 mL of water was added, and the pH was adjusted to 3 with 1 M hydrochloric acid. The mixture was extracted three times with 30 mL of ethyl acetate each time. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain (S)-3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionic acid, i.e., A-13. 0.6 mmol of A-13 was dissolved in a solvent, and 3.0 mmol of base and 1.2 mmol of condensing agent were added. The mixture was reacted at room temperature for 0.5 h, and then 0.6 mmol of intermediate was added. The mixture was reacted at room temperature overnight. After the reaction was completed, the reaction solution was slowly poured into a 50 mL ice-water mixture. The reaction solution was extracted three times with 30 mL of ethyl acetate each time. The organic phase was collected, filtered with anhydrous Na2SO4, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain a solid compound. The intermediate is one of C2-4, C3-4, C4-4, and C5-4; The solvent is selected from one or a mixture of more than one of N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, dichloromethane, tetrahydrofuran or 1,4-dioxane, preferably N,N-dimethylformamide; The base may be one or a mixture of more than one of triethylamine, N,N-diisopropylethylamine, triethylenediamine, 1,8-diazabicycloundec-7-ene, potassium carbonate, sodium carbonate or sodium bicarbonate, preferably triethylamine; The condensing agent is selected from one or a mixture of multiple of benzotriazole-N,N,N',N'-tetramethylurea hexafluorophosphate, 1H-benzotriazole-1-yloxytripyrrolyl hexafluorophosphate, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate, 1-hydroxybenzotriazole or 1-hydroxy-7-azobenzenetriazole, preferably 1H-benzotriazole-1-yloxytripyrrolyl hexafluorophosphate.

5. The preparation method according to claim 3, characterized in that, The specific method for the second synthetic route is as follows: Preparation of A-15: 16.8 mmol of A-13 was dissolved in N,N-dimethylformamide, and 84 mmol of triethylamine and 22.6 mmol of 1H-benzotriazol-1-yloxytripyrrolidinyl hexafluorophosphate were added. After reacting at room temperature for 0.5 hours, 16.8 mmol of 2-(piperazin-1-yl)pyrimidin-5-carboxylic acid methyl ester hydrochloride C1-2 was added, and the reaction was carried out overnight at room temperature. After the reaction was completed, the reaction solution was slowly poured into 50 mL of ice-water mixture and extracted three times with 10 mL of ethyl acetate each time. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product was purified by silica gel column chromatography with dichloromethane:methanol = 10:1 as the eluent to obtain (S)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidin-5-carboxylic acid methyl ester, i.e., A-14. Step 10: Dissolve 6.04 mmol of (S)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidine-5-carboxylic acid methyl ester (A-14) in a mixed solvent of 30 mL methanol and 5 mL water. Add 60.4 mmol of lithium hydroxide monohydrate and react at room temperature for 2 hours. Rotate the reaction mixture to dryness, add 30 mL water, adjust the pH to 3 with 1 M hydrochloric acid, and extract three times with 30 mL of ethyl acetate each time. Combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to obtain (S)-2-(4-(3-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)propionyl)piperazin-1-yl)pyrimidine-5-carboxylic acid, i.e., A-15. 0.2 mmol of A-15 was dissolved in a solvent, and 1.0 mmol of base and 1.2 mmol of condensing agent were added. The mixture was reacted at room temperature for 0.5 h, and then 0.2 mmol of intermediate was added. The mixture was reacted at room temperature overnight. After the reaction was completed, the reaction solution was slowly poured into a 50 mL ice-water mixture. The reaction solution was extracted three times with 10 mL of ethyl acetate each time. The organic phase was collected, filtered with anhydrous Na2SO4, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to obtain a solid compound. The intermediate is one of B1-2, B2-2, B3-2, B4-2, B5-2, B6-2, B7-2, B8-1, B9-2, C2-4, C3-4, C6-4, D1-2, D2-2, E1-4, E2-4, and E3-4; The solvent is selected from one or a mixture of more than one of N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, dichloromethane, tetrahydrofuran or 1,4-dioxane, preferably N,N-dimethylformamide; The base may be one or a mixture of more than one of triethylamine, N,N-diisopropylethylamine, triethylenediamine, 1,8-diazabicycloundec-7-ene, potassium carbonate, sodium carbonate or sodium bicarbonate, preferably triethylamine; The condensing agent is selected from one or a mixture of multiple of benzotriazole-N,N,N',N'-tetramethylurea hexafluorophosphate, 1H-benzotriazole-1-yloxytripyrrolyl hexafluorophosphate, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate, 1-hydroxybenzotriazole or 1-hydroxy-7-azobenzenetriazole, preferably 1H-benzotriazole-1-yloxytripyrrolyl hexafluorophosphate.

6. The preparation method according to claim 5, characterized in that, The preparation method of C1-2 is as follows: At 25°C, 10.7 mmol of potassium carbonate was added to 100 mL of a solution of 5.37 mmol of 1-(tert-butyloxycarbonyl)piperazine and 5.37 mmol of 2-chloro-5-(methyl carboxylate)pyrimidine. The reaction mixture was stirred at 80°C for 1 hour. After the reaction was completed, the reaction solution was slowly poured into 500 mL of an ice-water mixture and filtered to obtain methyl 2-[4-(tert-butyloxycarbonyl)piperazin-1-yl]pyrimidine-5-carboxylate, i.e., C1-1. At 0 °C, 4 M HCl / ethyl acetate solution was slowly added to 1.50 mmol of C1-1, and the reaction mixture was stirred at 25 °C for 3 hours; the mixture was filtered to give methyl 2-(piperazin-1-yl)pyrimidine-5-carboxylic acid hydrochloride, i.e., C1-2.

7. The use of any one of the pyridazinone derivatives according to claims 1-2 in the preparation of dual-target inhibitors of PARP7 and NAMPT.

8. Use of the pyridazinone derivative of any one of claims 1-2 in the preparation of a medicament for the prevention and / or treatment of tumors.

9. The application according to claim 8, characterized in that, The tumor is selected from one or more of the following: breast cancer, ovarian cancer, prostate cancer, colon cancer, gastric cancer, non-small cell lung cancer, glioma, kidney cancer, pancreatic cancer, liver cancer, melanoma, leukemia, and cervical cancer.

10. The application according to claim 9, characterized in that, The drug also includes one or more other anti-tumor drugs, immunotherapy drugs, chemotherapy drugs or targeted therapy drugs, and the pyridazinone derivative is used in combination with the other drugs.